Equities

Lupin Ltd

Lupin Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)2,195.30
  • Today's Change-53.25 / -2.37%
  • Shares traded800.07k
  • 1 Year change+82.97%
  • Beta0.7316
Data delayed at least 15 minutes, as of Oct 16 2024 11:24 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Lupin Limited is an India-based innovation-led transnational pharmaceutical company. The Company develops and commercializes a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The Company has a presence in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and others. Its complex generics portfolio includes Filgrastim, Pegfilgrastim, Etanercept and Albuterol and others. Its biosimilar products include Lupifil (Filgrastim), Lupifil-P (Peg-Filgrastim) and Etanercept. Its diabetes brands include ONDERO and ONDERO MET. The Company has 15 manufacturing sites, seven research centers, and more than 20,000 professionals working globally.

  • Revenue in INR (TTM)207.97bn
  • Net income in INR22.64bn
  • Incorporated1983
  • Employees21.87k
  • Location
    Lupin Ltd3rd Floor,Kalpataru Inspire,, Off. Western ExpressMUMBAI 400055IndiaIND
  • Phone+91 2 266402323
  • Fax+91 2 266402051
  • Websitehttps://www.lupin.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Abbott India Ltd59.28bn12.39bn616.66bn3.81k49.77--47.0210.40583.08583.082,789.54--------15,541,480.00--20.92--28.5945.2844.2020.9017.26--119.46--77.069.359.7226.5221.6831.0852.32
Alkem Laboratories Ltd127.32bn20.54bn749.13bn17.28k36.47--31.465.88171.81171.811,064.87--------7,369,150.00--11.88--17.5062.2159.2616.2913.94--9.12--29.829.2111.4882.4718.75-13.3020.11
Aurobindo Pharma Ltd297.18bn35.21bn859.62bn8.80k24.62--16.902.8960.1260.12507.19--------33,782,390.00--9.24--13.4357.8753.3011.8412.72--13.17--8.6416.688.1964.626.0617.9612.47
Lupin Ltd207.97bn22.64bn1.03tn21.87k45.47--31.154.9449.5049.50454.84--------9,510,284.00--1.43--2.2267.5858.5211.002.04--9.67--75.0320.256.41345.1530.18-1.179.86
Zydus Lifesciences Ltd206.15bn41.69bn1.06tn26.24k25.64--21.375.1641.2841.51204.01--------7,856,441.00--9.05--14.0170.2261.1520.2914.33------16.4813.408.2395.2515.72-3.03-3.04
Mankind Pharma Ltd106.50bn19.63bn1.10tn19.54k56.17--45.6910.3448.9148.91265.43--------5,450,142.00--------69.93--18.69----90.42----18.12--49.23------
Dr Reddy's Laboratories Ltd289.49bn55.65bn1.10tn26.34k19.81--15.603.80333.72333.721,735.89--------10,989,370.00--11.37--16.0270.8065.8619.2214.63--36.60--15.9113.5412.6423.7523.3926.7814.87
Torrent Pharmaceuticals Ltd109.96bn17.35bn1.18tn14.92k68.22--46.6710.7751.2751.27324.85--------7,371,843.00--8.34--13.0375.1771.7815.7813.18--8.19--61.6511.516.9333.0230.58-8.1726.93
Cipla Ltd261.39bn43.03bn1.27tn27.76k29.50--23.534.8653.2753.27323.59--------9,414,760.00--10.09--12.4066.4358.6316.5812.66--59.65--21.3913.289.5147.1021.9620.6834.08
Data as of Oct 16 2024. Currency figures normalised to Lupin Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

28.12%Per cent of shares held by top holders
HolderShares% Held
Life Insurance Corporation of India (Investment Portfolio)as of 30 Sep 202337.49m8.22%
ICICI Prudential Asset Management Co. Ltd.as of 30 Sep 202323.39m5.13%
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 30 Sep 202316.73m3.67%
The Vanguard Group, Inc.as of 04 Jul 20249.04m1.98%
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Jul 20248.29m1.82%
HDFC Life Insurance Co. Ltd. (Investment Portfolio)as of 30 Sep 20237.66m1.68%
Mirae Asset Investment Managers (India) Pvt Ltd.as of 30 Sep 20237.66m1.68%
BlackRock Fund Advisorsas of 04 Jul 20246.36m1.40%
Norges Bank Investment Managementas of 30 Sep 20236.27m1.38%
SBI Funds Management Ltd.as of 30 Jun 20245.33m1.17%
More ▼
Data from 31 Dec 2023 - 08 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.